16th International Congress of the Society for Melanoma Research (SMR)

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Grand America Hotel
Salt Lake City, UT, United States
Nov 20, 2019 - Nov 23, 2019
This is a global congress that unites melanoma clinicians and researchers to focus on multidisciplinary management of melanoma/skin cancer.
Visit the conference website for more details.

News

SMR 2019: Concurrent Intrathecal + IV Nivolumab Proves Safe in Patients With Melanoma and Leptomeningeal Metastasis

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: Lifileucel Therapy Leads to Durable Response in Heavily Pretreated, Refractory, Advanced Melanoma

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: After 5 Years, Cobimetinib + Vemurafenib Continues to Provide Long-Term Clinical Benefit in BRAF V600-Mutated Metastatic Melanoma

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: After 24 Months, Pembrolizumab + Dabrafenib + Trametinib Continues to Improve Outcomes in BRAF-Mutated Melanoma

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: Adjuvant Immunotherapy for SNL+ Melanoma With Completion Lymph Node Dissection May Be as Effective as Without Such Dissection

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: Circulating Tumor Cell Scores Could Help Prognosticate and Monitor Treatment Response Monitoring in Metastatic Melanoma

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: Encorafenib + Binetinib Under Evaluation for Brain Metastasis of BRAF V600-Mutant Melanoma

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: Neoadjuvant T-VEC Improves 2-Year Recurrence-Free and Overall Survival in Resectable Stage 3B-4M1a Melanoma

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: A 31-Gene Expression Profile Test Can Identify Low Risk of Sentinel Lymph Node Positivity in Patients ≥65 Years of Age With Cutaneous Melanoma

PracticeUpdate Editorial Team · March 11, 2020

SMR
SMR 2019: The Hypothesized Mechanism of Action of Tebentafusp-Induced T Cell Redirection and Activation Is Supported

PracticeUpdate Editorial Team · November 25, 2019

SMR

16th International Congress of the Society for Melanoma Research (SMR)

News

SMR 2019: Concurrent Intrathecal + IV Nivolumab Proves Safe in Patients With Melanoma and Leptomeningeal Metastasis

SMR 2019: Lifileucel Therapy Leads to Durable Response in Heavily Pretreated, Refractory, Advanced Melanoma

SMR 2019: After 5 Years, Cobimetinib + Vemurafenib Continues to Provide Long-Term Clinical Benefit in BRAF V600-Mutated Metastatic Melanoma

SMR 2019: After 24 Months, Pembrolizumab + Dabrafenib + Trametinib Continues to Improve Outcomes in BRAF-Mutated Melanoma

SMR 2019: Adjuvant Immunotherapy for SNL+ Melanoma With Completion Lymph Node Dissection May Be as Effective as Without Such Dissection

SMR 2019: Circulating Tumor Cell Scores Could Help Prognosticate and Monitor Treatment Response Monitoring in Metastatic Melanoma

SMR 2019: Encorafenib + Binetinib Under Evaluation for Brain Metastasis of BRAF V600-Mutant Melanoma

SMR 2019: Neoadjuvant T-VEC Improves 2-Year Recurrence-Free and Overall Survival in Resectable Stage 3B-4M1a Melanoma

SMR 2019: A 31-Gene Expression Profile Test Can Identify Low Risk of Sentinel Lymph Node Positivity in Patients ≥65 Years of Age With Cutaneous Melanoma

SMR 2019: The Hypothesized Mechanism of Action of Tebentafusp-Induced T Cell Redirection and Activation Is Supported

No Content

Recently Updated